COMPARISON
Lanreotide vs Teduglutide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Lanreotide is authorised or registered in 9 and Teduglutide in 7 of the 10 registers read. Lanreotide: highest phase Phase 4 (after approval). Teduglutide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Lanreotide | Teduglutide | |
|---|---|---|
| Registered trials differs | 125 clinicaltrials.gov · 2026-10-03 | 51 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Lanreotide Acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Gattex openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for lanreotide | 2012-08-30 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for lanreotide | A16AX08 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Lanreotide | placebo | Teduglutide | placebo |
|---|---|---|---|---|
| Abdominal pain | 16.8% | 15.9% | 31.0% | 23.3% |
| Nausea | 11.0% | 12.0% | 28.6% | 18.6% |
| Vomiting | 10.8% | 7.8% | 11.9% | 9.3% |
| Diarrhoea | 19.5% | 23.6% | - | - |
| Fatigue | 12.2% | 14.6% | - | - |
| Headache | 10.7% | 9.4% | - | - |
| Hypertension | 8.8% | 5.6% | - | - |
| Arthralgia | 8.0% | 8.2% | - | - |
| Back pain | 8.0% | 10.3% | - | - |
| Decreased appetite | 8.0% | 8.6% | - | - |
| Gastrointestinal stoma complication | - | - | 23.8% | 7.0% |
| Abdominal distension | - | - | 21.4% | 2.3% |
| Central line systemic infections | - | - | 16.7% | 16.3% |
| Edema peripheral | - | - | 16.7% | 4.7% |
| Urinary tract infection | - | - | 14.3% | 9.3% |
| Flatulence | - | - | 11.9% | 7.0% |
| Catheter-related infection | - | - | 11.9% | 2.3% |
Trial register Lanreotide: 5 placebo-controlled trials; Teduglutide: 1. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Lanreotide side effects · Teduglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Lanreotide | Teduglutide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Not on the register | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.